Literature DB >> 34256308

Myeloid-associated lipin-1 transcriptional co-regulatory activity is atheroprotective.

Cassidy M R Blackburn1, Robert M Schilke1, Aimee E Vozenilek1, Sunitha Chandran1, Temitayo T Bamgbose1, Brian N Finck2, Matthew D Woolard3.   

Abstract

BACKGROUND AND AIMS: Atherosclerosis is the most prominent underlying cause of cardiovascular disease (CVD). It is initiated by cholesterol deposition in the arterial intima, which causes macrophage recruitment and proinflammatory responses that promote plaque growth, necrotic core formation, and plaque rupture. Lipin-1 is a phosphatidic acid phosphohydrolase for glycerolipid synthesis. We have shown that lipin-1 phosphatase activity promotes macrophage pro-inflammatory responses when stimulated with modified low-density lipoprotein (modLDL) and accelerates atherosclerosis. Lipin-1 also independently acts as a transcriptional co-regulator where it enhances the expression of genes involved in β-oxidation. In hepatocytes and adipocytes, lipin-1 augments the activity of transcription factors such as peroxisome proliferator-activated receptor (PPARs). PPARs control the expression of anti-inflammatory genes in macrophages and slow or reduce atherosclerotic progression. Therefore, we hypothesize myeloid-derived lipin-1 transcriptional co-regulatory activity reduces atherosclerosis.
METHODS: We used myeloid-derived lipin-1 knockout (lipin-1mKO) and littermate control mice and AAV8-PCSK9 along with high-fat diet to elicit atherosclerosis.
RESULTS: Lipin-1mKO mice had larger aortic root plaques than littermate control mice after 8 and 12 weeks of a high-fat diet. Lipin-1mKO mice also had increased serum proinflammatory cytokine concentrations, reduced apoptosis in plaques, and larger necrotic cores in the plaques compared to control mice.
CONCLUSIONS: Combined, the data suggest lipin-1 transcriptional co-regulatory activity in myeloid cells is atheroprotective.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; IL-23; Lipin-1 transcriptional co-regulatory activity; Macrophage; Necrotic core

Mesh:

Substances:

Year:  2021        PMID: 34256308      PMCID: PMC8328963          DOI: 10.1016/j.atherosclerosis.2021.06.927

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   6.847


  49 in total

1.  Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling.

Authors:  Manikandan Subramanian; Edward Thorp; Ira Tabas
Journal:  Circ Res       Date:  2014-10-27       Impact factor: 17.367

2.  Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms.

Authors:  Joost P G Sluijter; Wilco P C Pulskens; Arjan H Schoneveld; Evelyn Velema; Chaylendra F Strijder; Frans Moll; Jean-Paul de Vries; Jan Verheijen; Roeland Hanemaaijer; Dominique P V de Kleijn; Gerard Pasterkamp
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

3.  Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.

Authors:  J Frostegård; A K Ulfgren; P Nyberg; U Hedin; J Swedenborg; U Andersson; G K Hansson
Journal:  Atherosclerosis       Date:  1999-07       Impact factor: 5.162

4.  The Effects of Anti-IL-23p19 Therapy on Atherosclerosis Development in ApoE-/- Mice.

Authors:  Jun Wang; Pei Zhao; Yang Gao; Fengyu Zhang; Xiaochen Yuan; Yungen Jiao; Kaizheng Gong
Journal:  J Interferon Cytokine Res       Date:  2019-07-02       Impact factor: 2.607

5.  Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion.

Authors:  Zhouji Chen; Matthew C Gropler; Jin Norris; John C Lawrence; Thurl E Harris; Brian N Finck
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

6.  Lipin-1 contributes to modified low-density lipoprotein-elicited macrophage pro-inflammatory responses.

Authors:  Aaron R Navratil; Aimee E Vozenilek; James A Cardelli; Jonette M Green; Michael J Thomas; Mary G Sorci-Thomas; A Wayne Orr; Matthew D Woolard
Journal:  Atherosclerosis       Date:  2015-08-10       Impact factor: 5.162

7.  AAV8-mediated overexpression of mPCSK9 in liver differs between male and female mice.

Authors:  Aimee E Vozenilek; Cassidy M R Blackburn; Robert M Schilke; Sunitha Chandran; Reneau Castore; Ronald L Klein; Matthew D Woolard
Journal:  Atherosclerosis       Date:  2018-09-08       Impact factor: 5.162

Review 8.  C-reactive protein, inflammation, and coronary risk.

Authors:  Paul M Ridker; David A Morrow
Journal:  Cardiol Clin       Date:  2003-08       Impact factor: 2.213

9.  Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis.

Authors:  Adil Rasheed; Sabrina Robichaud; My-Anh Nguyen; Michele Geoffrion; Hailey Wyatt; Mary Lynn Cottee; Taylor Dennison; Antonietta Pietrangelo; Richard Lee; Thomas A Lagace; Mireille Ouimet; Katey J Rayner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-26       Impact factor: 8.311

10.  Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages.

Authors:  Evanna L Mills; Beth Kelly; Angela Logan; Ana S H Costa; Mukund Varma; Clare E Bryant; Panagiotis Tourlomousis; J Henry M Däbritz; Eyal Gottlieb; Isabel Latorre; Sinéad C Corr; Gavin McManus; Dylan Ryan; Howard T Jacobs; Marten Szibor; Ramnik J Xavier; Thomas Braun; Christian Frezza; Michael P Murphy; Luke A O'Neill
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

View more
  1 in total

Review 1.  Inflammation Resolution: Implications for Atherosclerosis.

Authors:  Amanda C Doran
Journal:  Circ Res       Date:  2022-01-07       Impact factor: 17.367

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.